Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy

Overview of attention for article published in Frontiers in oncology, October 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 9 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 9,790 followers.

Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy https://t.co/njIQ8UGRXi

11 Nov 2021

Reply Repost Favourite

Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy #lymphoma #lymsm https://t.co/4hjskOtKsM

02 Nov 2021

Reply Repost Favourite

Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy #lymphoma #lymsm https://t.co/gVl4UY9npB

01 Nov 2021

Reply Repost Favourite

New research: Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy: Sarcoma or sarcomatoid malignancies are a set of mesenchymal-origin malignancies with vast heterogeneity in clinical… https://t.c

14 Oct 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.